In the last five years, significant insights into PV biology and treatment, as well as data spanning clinical pharmacokinetic (PK)/pharmacodynamic (PD) relationships, safety and efficacy, have emerged with interferon (IFN)-based therapies. The gene discussed is IFNA1; the disease is acquired polycythemia vera.